Nifedipine Tablet, Extended Release
Product Images NDC 51407-623

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Nifedipine (NDC 51407-623). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

51407-622-01 (51407 622 01)

Each extended-release film-coated tablet contains 30 mg Nifedipine, USP. Dosage instructions are mentioned in the accompanying Prescribing Information. Tablets should be swallowed whole and not bitten or divided. The tablets need to be protected from light and moisture and dispensed in a tight, light-resistant container as defined in the USP by the pharmacist. The medication needs to be kept out of children's reach and stored at the recommended temperature. The tablets are manufactured by Novast Laboratories Ltd. and marketed by GSMS, Incorporated. This document has a revision date of 02/22.*

FDA Label Image

51407-623-01 (51407 623 01)

This is a packaging description for a medication called Nifedipine. Each extended-release tablet contains 60 mg of Nifedipine. The dosage instructions are not provided and it is advised to refer to the prescribing information. The tablets should not be split or bitten, and must be swallowed whole. The medication should be protected from light and moisture and kept in a container resistant to light. The medication needs to be stored in a controlled room temperature between- 20°C to 25°C. The manufacturer is Novast Laboratories Ltd, marketed by GSMS, Inc in Camarillo. The product is available only with a prescription.*

FDA Label Image

51407-624-01 (51407 624 01)

Each extended-release film-coated tablet contains 90 mg Nifedipine, USP. Tablets should be swallowed whole and not bitten or divided. The tablets must be protected from light and moisture and dispensed in a tight, light-resistant container. The medication should be kept out of reach of children and stored at 20° - 25°C (68° - 77°F). This information is available for pharmacists and for those who have access to the prescribing information. Manufactured by Novast Laboratories Ltd. and marketed by GSMS, Incorporated. This medication is available only with a prescription.*

FDA Label Image

Image1 (Image 01)

FDA Label Image

Image2 (Image 02)

This text displays the mean reductions in trough supine blood pressure for systolic and diastolic values in two studies using different doses of Nifedipine ER tablets. The first study used doses of 30, 60, and 90mg and had 60, 57, and 55 participants, respectively. The second study also used doses of 30, 60, and 90mg but had 58, 63, and 62 participants, respectively. The placebo response was subtracted from the results. Nifedipine ER refers to Nifedipine extended-release tablets.*

FDA Label Image

Image3 (Image 03)

This table shows the percentage of adverse effects experienced by patients taking Nifedipine extended-release tablets compared to those on placebo. The adverse effects listed include headache, flushing/heat sensation, dizziness, fatigue/asthenia, nausea, and constipation. The number of patients (n) included in the study was 370 for the Nifedipine group and 126 for the placebo group.*

FDA Label Image

Image4 (Image 04)

This is a description of a medication with three different strengths: 30mg, 60mg and 90mg. Each pill has a different color and has markings on both sides - with the name "Novast" on one side and the respective numbers "33," "36," or "39" on the other side. The 30mg pill is yellow, the 60mg pill is pink and the 90mg pill is brown. These markings and colors may be helpful for identifying the strength of the medication.*

FDA Label Image

Image6 (Image 06)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.